Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03936959 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer
A Phase 1 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT03936959 is a Phase 1 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 10 participants.
The verdict
NCT03936959, a Phase 1 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the safety and tolerability of the study drug LY3434172, a PD-1/PD-L1 bispecific antibody, in participants with advanced solid tumors.
Interventions
- DRUG LY3434172
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-05-24 |
| Est. Completion | 2021-04-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03936959
The ClinicalTrials.gov registry entry for NCT03936959 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LY3434172 is the first listed.
NCT03936959 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03936959 about?
NCT03936959 is a clinical study titled "A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer". The main purpose of this study is to evaluate the safety and tolerability of the study drug LY3434172, a PD-1/PD-L1 bispecific antibody, in participants with advanced solid tumors.
What is the current status of trial NCT03936959?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2019-05-24. Estimated completion is 2021-04-29.
What interventions are being tested in trial NCT03936959?
The interventions under investigation include: LY3434172 (DRUG).
Who is sponsoring clinical trial NCT03936959?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.